<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0008336.ref038">
 <label>38</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Buac</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Shen</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Schmitt</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Kona</surname>
   <given-names>FR</given-names>
  </name>, 
  <name>
   <surname>Deshmukh</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Zhang</surname>
   <given-names>Z</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>From bortezomib to other inhibitors of the proteasome and beyond.</article-title>
  <source>Curr Pharm Des</source>. 
  <year>2013</year>;
  <volume>19</volume>(
  <issue>22</issue>):
  <fpage>4025</fpage>â€“
  <lpage>38</lpage>. 
  <pub-id pub-id-type="doi">10.2174/1381612811319220012</pub-id>
  <?supplied-pmid 23181572?>
  <pub-id pub-id-type="pmid">23181572</pub-id>
 </mixed-citation>
</ref>
